The Ohio State University Comprehensive Cancer Center

The James Cancer Hospital and Solove Research Institute

About This Center

Every person’s cancer is different, with individually unique genes and molecules driving that disease. At the OSUCCC – James, our blood cancer subspecialists are world-renowned experts who focus solely on blood and bone marrow disorders and who work together across medical disciplines (hematologists, radiation oncologists, molecular and biological pathologists, genetic scientists and more) to develop individualized, highly targeted treatment plans and therapies that specifically target the molecular and biological makeup of your individual cancer.

Myeloma Clinical Trials

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

This is an investigational immuno-therapy study that is designed to test the effectiveness, safety, and tolerability of an investigational drug called nivolumab. The study will determine the safety in subjects that receive nivolumab when given in combination with daratumumab, or dartartumumab alone in relapsed and/or refractory multiple myeloma.

Learn more about this trial


Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource

The investigators are researching patients with diseases of their plasma cells in order to improve their quality and length of life.

Learn more about this trial



A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

The primary objective of this study is to determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free survival (PFS) compared with active monitoring in participants with high-risk smoldering multiple myeloma (SMM).

Learn more about this trial


Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma (MASTER)

This trial will assess the safety and efficacy of an induction therapy using the combination of dexamethasone, lenalidomide (revlimid), daratumumab (Darzalex) and carfilzomib (Kyprolis) to treat patients with newly diagnosed multiple myeloma. The therapy with KRdD (Kyprolis, Revlimid, dexamethasone, Darzalex) will be followed by autologous hematopoietic cell transplantation (auto-HCT) and KRdD consolidation. The hypothesis is that the KRdD therapy particularly in combination with the auto-HCT will be safe and lead to deep remission. The trial will also assess the monitoring for minimal residual disease (MRD) resurgence to determine if continuous therapy is needed or discontinuation of therapy.

Learn more about this trial


Open-label, randomized study of two doses of GSK2857916 in participants with relapsed / refractory multiple myeloma who have failed prior treatment of an anti-CD38 antibody and are refractory to an immunomodulatory agent and a proteasome inhibitor

This research study is being done to learn more about multiple myeloma and if the study drug, GSK2857916, can improve multiple myeloma in patients who have already failed other treatments.

Learn more about this trial


Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)

This is a Phase 1/2 study designed to evaluate the safety and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma whose disease has progressed after 3 or more prior systemic therapies.

Learn more about this trial


Myeloma-Developing Regimens Using Genomics (MyDRUG)

The MyDRUG study is a type of Precision Medicine trial to treat patients with drugs targeted to affect specific genes that are mutated as part of the disease. Mutations in genes can lead to uncontrolled cell growth and cancer. Patients with a greater than 30% mutation to any of the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled to one of the treatment arms.

Learn more about this trial


MMRF Molecular Profiling Protocol

The purpose of the Molecular Profiling Initiative (MPI) is to provide timely CLIA genomic sequencing information to MM patients and their doctors, allowing them to make informed treatment decisions and identify potential treatment options based on a patient’s genomic alterations.

Learn more about this trial


Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma

The purpose of this first in human study is to assess safety, tolerability, PK and preliminary clinical activity and to estimate the MTD(s)/RDE(s) of MIK665 (also referred as S64315) as single agent administered intravenously (i.v.) in adult patients with refractory or relapsed lymphoma or multiple myeloma.

Learn more about this trial


Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)

The study is designed as a Phase II, multicenter trial of vaccination with Dendritic cell/myeloma fusions with granulocyte macrophage colony-stimulating factor (GM-CSF) adjuvant plus lenalidomide maintenance therapy versus maintenance therapy alone or with GM-CSF following autologous transplant as part of upfront treatment of multiple myeloma. It is hypothesized that the dendritic cell myeloma vaccine will result in improved response in patients with multiple myeloma after autologous HCT.

Learn more about this trial


Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

This phase I/II trial studies the side effects and best dose of idasanutlin and ixazomib citrate when given together with dexamethasone in treating patients with multiple myeloma that has returned after a period of improvement.

Learn more about this trial


Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma

The purpose of this research study is to evaluate a treatment regimen called IRD which will be given to participants after their stem cell transplant in an effort to help prolong the amount of time the participants are disease-free after transplant.

Learn more about this trial


Study of Melflufen + Dex With Bortezomib or Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma

This is an open-label Phase 1/2a study which will enroll patients that have relapsed or relapsed-refractory multiple myeloma following 1-4 lines of prior therapy.

Learn more about this trial


Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies

This study is a multicenter, open-label, nonrandomized, sequential group, dose-escalation study to assess safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ascending doses of AZD5991 in subjects with relapsed or refractory hematologic malignancies.

Learn more about this trial


A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

The purpose of this study to determine if the addition of daratumumab to bortezomib + lenalidomide + dexamethasone (VRd) will improve overall minimal residual disease (MRD) negativity rate compared with VRd alone.

Learn more about this trial


A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory Multiple Myeloma

The purpose of this Phase 1 portion of the study is to determine the safety and tolerability of TAK-573 monotherapy in participants with refractory multiple myeloma (MM) and Phase 2a portion of the study is to provide a preliminary evaluation of the clinical activity of TAK-573 monotherapy in participants with refractory MM.

Learn more about this trial


A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

This study is designed to evaluate the safety and preliminary efficacy of venetoclax combined with pomalidomide and dexamethasone in subjects with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least 1 prior line of therapy. The study will consist of 2 parts: Part 1 (dose escalation) and Part 2 (dose expansion). For Part 2 the subjects will be divided into 2 cohorts, subjects positive for t(11;14) translocation and subjects negative for t(11;14) translocation.

Learn more about this trial


Viral Protein Production After Dexamethasone, Wild-Type Reovirus, and Carfilzomib in Treating Patients With Multiple Myeloma

This pilot clinical trial studies the activity of dexamethasone, wild-type reovirus, and carfilzomib in patients with multiple myeloma and viral protein production following treatment. Drugs used in chemotherapy, such as dexamethasone and carfilzomib, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. A virus called wild-type reovirus may be able to kill cancer cells without damaging normal cells and seems to work best when given with chemotherapy. Giving wild-type reovirus with chemotherapy may be a more active treatment than chemotherapy alone.

Learn more about this trial


HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma

This pilot phase I trial studies the side effects and best dose of histone deacetylase (HDAC) inhibitor AR-42 (AR-42) when given together with pomalidomide in treating patients with multiple myeloma that has returned after a period of improvement.

Learn more about this trial


Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma

This is a phase 1, multi-center, single-arm, open-label study evaluating the safety, tolerability, and anti-myeloma activity of ACTR087 (an autologous T cell product) in combination with SEA-BCMA (a monoclonal antibody) in subjects with relapsed or refractory Multiple Myeloma.

Learn more about this trial

Center Information

460 West 10th Avenue
Columbus, OH 43210

Find a Specialist

Create your account today and get matched to myeloma treatment centers and specialists around the US.

  • Find centers with eligible clinical trials.
  • Get a second opinion from a myeloma specialist.
  • Receive alerts when new trials become available.
  • Our services are always free for patients and HIPAA compliant.

Create Account


Need Help?

(888) 828-2206

Weekdays 9am - 5pm EST

;